Levels of Circulating T Cells Expressing VLA-1 Collagen Receptors

The examination of the percentage of peripheral T cells carrying VLA-1 in ischemic heart disease patients. The hypothesis is that the percentage levels of cells carrying this integrin rise according to the severity of the ischemic heart disease.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Ischemic Heart Disease Cardiovascular Diseases Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

About this study

Atherosclerosis is considered an inflammatory disease in which lymphocytes have an important role. The study was disigned to find out the changes in T cell levels carrying VLA-1 involvement in this process.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

clinical diagnosis of acute MI for group 1
clinical diagnosis of ACSl for group 2
clinical diagnosis of Chronic Heart Disease for groups 3 and 4
Chest pain but normal heart scan for group 5

Exclusion criteria

none

Treatment and study plan

Primary outcomes

The differance in percentage of T cells in the 5 different groups involved.

Time frame: 2002-2006

Sponsors and collaborators

Lead sponsor

Sheba Medical Center

Other Gov

Registry information

Official study title

VLA-1 Receptors on Peripheral T Cells in Ischemic Heart Disease Patients

Important dates

Study start: 2002
Primary completion: 2006
Study completion: 2007
First posted: Jul 2, 2008
Registry last updated: Jul 2, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed